Kymera Therapeutics rose 2.2-fold in a year. Moderna rose 9.8-fold.

Same industry

KYMR against four biotech peers, a year at 100

KYMR is up 2.2 times in a year. Moderna is up 9.8 times. Of these four, Biogen (+56.9%), Amgen (+43.8%) and Gilead Sciences (+41.0%) did less. Weekly closes, Nov 7, 2025 = 100, on a log scale so a 9.8-fold rise and a 41.0% rise both read honestly.

Share this chart

KYMR ×2.2. Moderna ×9.8, Biogen +56.9%, Amgen +43.8%, Gilead Sciences +41.0%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in KYMR’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

KYMR: stories, the record and filings →